Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Nordic Bioscience A/S Novartis |
---|---|
Information provided by: | Nordic Bioscience A/S |
ClinicalTrials.gov Identifier: | NCT00704847 |
The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis |
Drug: Oral Salmon Calcitonin Drug: Oral Salmon Calcitonin (Placebo) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis |
Estimated Enrollment: | 920 |
Study Start Date: | June 2008 |
Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
SMC021 Oral Calcitonin
|
Drug: Oral Salmon Calcitonin
0.8mg SMC021, twice daily
|
2: Placebo Comparator
SMC021 Placebo
|
Drug: Oral Salmon Calcitonin (Placebo)
0.8mg Placebo, twice daily
|
Ages Eligible for Study: | 51 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply
United States, Alabama | |
Achieve Clinical Research, LLC | |
Tuscaloosa, Alabama, United States, 35406 | |
United States, California | |
Center for Healthy Aging | |
Sacramento, California, United States, 95817 | |
United States, Illinois | |
Northwestern Center for Clinical Research | |
Chicago, Illinois, United States, 60611 | |
United States, Missouri | |
Midwest Pharmaceutical Research | |
St. Peters, Missouri, United States, 63376 | |
United States, North Carolina | |
Thurston Arthritis Research Center | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Ohio | |
Rheumatology Clinical Research Unit | |
Beachwood, Ohio, United States, 44122 | |
Belgium | |
Hospital Universitaire St. Luc, UCL 5390 | |
Brussels, Belgium, 1200 | |
Canada | |
Centre de Rhumatologie St-Louis | |
Sainte-Foy (Québec), Canada, G1W 4R4 | |
Czech Republic | |
CCBR Czech | |
Pardubice, Czech Republic, 53002 | |
Denmark | |
CCBR Aalborg | |
Aalborg, Denmark, 9000 | |
CCBR Ballerup | |
Ballerup, Denmark, 2750 | |
CCBR Vejle | |
Vejle, Denmark, 7100 | |
Hong Kong | |
CCBR Hong Kong | |
Hong Kong, Hong Kong | |
Poland | |
CCBR Poland | |
Warsaw, Poland, 04703 | |
Centrum Osteoporozy i Chorób Kostno Stawowych, ul. Waryńskiego 6/2 | |
Bialystok, Poland, 15-461 | |
Romania | |
CCBR Romania | |
Bucharest, Romania, 030463 | |
Spain | |
Hospital Universitario de la Paz | |
Madrid, Spain, 28046 | |
United Kingdom | |
Little Common Surgery | |
East Sussex, United Kingdom, TN 39 4SP |
Study Director: | Bente Juul Riis, MD | Nordic Bioscience |
Responsible Party: | Nordic Bioscience A/S ( Bente Juel Riis ) |
Study ID Numbers: | CSMC021C2302 |
Study First Received: | June 24, 2008 |
Last Updated: | April 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00704847 History of Changes |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board; Denmark: Danish Dataprotection Agency; Denmark: Danish Medicines Agency; Denmark: Ethics Committee; Czech Republic: Ethics Committee; Czech Republic: State Institute for Drug Control; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Romania: National Medicines Agency; Hong Kong: Department of Health; Hong Kong: Ethics Committee; Turkey: Ethics Committee; Turkey: Ministry of Health; United Kingdom: National Health Service; United Kingdom: Research Ethics Committee; Belgium: Directorate general for the protection of Public health: Medicines; Belgium: Institutional Review Board; France: Afssaps - French Health Products Safety Agency; France: Institutional Ethical Committee; Spain: Spanish Agency of Medicines; Spain: Comité Ético de Investigación Clínica; Canada: Health Canada; Canada: Ethics Review Committee |
Osteoarthritis, oral salmon calcitonin, treatment, efficacy, tolerability |
Calcitonin Gene-Related Peptide Calcitonin Osteoarthritis, Knee Vasodilator Agents Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Bone Density Conservation Agents Cardiovascular Agents Rheumatic Diseases Salmon calcitonin |
Calcitonin Vasodilator Agents Osteoarthritis Joint Diseases Physiological Effects of Drugs Bone Density Conservation Agents Cardiovascular Agents Rheumatic Diseases |
Salmon calcitonin Pharmacologic Actions Calcitonin Gene-Related Peptide Osteoarthritis, Knee Musculoskeletal Diseases Therapeutic Uses Arthritis |